Original paper
Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus
Abstract
Blood dendritic cell antigen 2 (BDCA2) is a receptor that is exclusively expressed on plasmacytoid dendritic cells, which are implicated in the pathogenesis of lupus erythematosus. Whether treatment with litifilimab, a humanized monoclonal antibody against BDCA2, would be efficacious in reducing disease activity in patients with cutaneous lupus erythematosus has not been extensively studied.In this phase 2 trial, we randomly assigned adults with...
Paper Details
Title
Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus
Published Date
Jul 27, 2022
Volume
387
Issue
4
Pages
321 - 331